Payment overview · 2025
General Payments
$487.45
7 reported records · 5 companies
Healthcare provider profile · identity verified
Jack P Spaniol, MD
Allopathic & Osteopathic Physicians|Family Medicine · BLOOMINGTON, IL · NPI 1356379184
Verified facts
What the public records show
CMS Open Payments records show Jack P Spaniol, MD received $487.45 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Nurtec Odt, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $173.41 | 35.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $110.88 | 22.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $110.70 | 22.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $72.77 | 14.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.69 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $438.91 | 5 |
| Education | $48.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.14 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $110.88 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $110.70 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $72.77 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $19.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 179 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
179 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 809 | 219 |
| Pantoprazole Sodium | Pantoprazole Sodium | 391 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 88 |
| Losartan Potassium | Losartan Potassium | 342 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 337 | 92 |
| Metformin Hcl | Metformin Hcl | 317 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 291 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 64 |
| Lisinopril | Lisinopril | 187 | 54 |
| Omeprazole | Omeprazole | 180 | 50 |
| Jardiance | Empagliflozin | 179 | 52 |
| Trulicity | Dulaglutide | 169 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 31 |
| Potassium Chloride | Potassium Chloride | 149 | 43 |
| Gabapentin | Gabapentin | 145 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 39 |
| Carvedilol | Carvedilol | 118 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 31 |
| Eliquis | Apixaban | 97 | 26 |
| Tramadol Hcl | Tramadol Hcl | 97 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 20 |
| Famotidine | Famotidine | 90 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 21 |
| Ozempic | Semaglutide | 84 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 21 |
| Alprazolam | Alprazolam | 80 | 17 |
| Furosemide | Furosemide | 80 | 27 |
| Glimepiride | Glimepiride | 79 | 23 |
| Meloxicam | Meloxicam | 73 | 18 |
| Prednisone | Prednisone | 72 | 35 |
| Trazodone Hcl | Trazodone Hcl | 72 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 20 |
| Pregabalin | Pregabalin | 71 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 68 | 12 |
| Montelukast Sodium | Montelukast Sodium | 68 | 22 |
| Sertraline Hcl | Sertraline Hcl | 68 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 24 |
| Spironolactone | Spironolactone | 61 | 21 |
| Allopurinol | Allopurinol | 60 | 16 |
| Nifedipine Er | Nifedipine | 59 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 26 |
| Chlorthalidone | Chlorthalidone | 54 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 13 |
| Warfarin Sodium | Warfarin Sodium | 54 | 11 |
| Lorazepam | Lorazepam | 50 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 18 |
| Azithromycin | Azithromycin | 47 | 31 |
| Diazepam | Diazepam | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 14 |
| Glipizide | Glipizide | 45 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 15 |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 34 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 28 | 13 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Estradiol | Estradiol | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $487.45 · 7 records | Novo Nordisk Inc | JARDIANCE, NURTEC ODT, Omnipod, Ozempic, THORATEC HEARTMATE 3 LVAS IMPLANT KIT | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error